Literature DB >> 12675510

Medical management of pituitary adenomas: structural and ultrastructural changes.

Sylvia L Asa1, Shereen Ezzat.   

Abstract

The morphology of the various pituitary cell types is highly dynamic and allows recognition of many cellular functions. Most pituitary cells show morphologic changes that reflect stimulation or inhibition by hormones. Drugs have also been shown to alter the morphology of several pituitary tumor types, allowing a measure of therapeutic efficiency and a careful dissection of the mechanisms of action of various medical therapies. In some cases, these morphologic alterations can evoke diagnostic problems.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12675510     DOI： 10.1023/a:1022320732718

Source DB:  PubMed          Journal:  Pituitary        ISSN： 1386-341X            Impact factor:   4.107


  37 in total

Review 1.  Fine structural cytology of the adenohypophysis in rat and man.

Authors:  E Horvath; K Kovacs
Journal:  J Electron Microsc Tech       Date:  1988-04

2.  Effects of corticotropin-releasing factor and other materials on adrenocorticotropin secretion from pituitary glands of patients with Cushing's disease in vitro.

Authors:  T Suda; N Tomori; F Tozawa; H Demura; K Shizume
Journal:  J Clin Endocrinol Metab       Date:  1984-11       Impact factor: 5.958

3.  Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.

Authors:  A J van der Lely; R K Hutson; P J Trainer; G M Besser; A L Barkan; L Katznelson; A Klibanski; V Herman-Bonert; S Melmed; M L Vance; P U Freda; P M Stewart; K E Friend; D R Clemmons; G Johannsson; S Stavrou; D M Cook; L S Phillips; C J Strasburger; S Hackett; K A Zib; R J Davis; J A Scarlett; M O Thorner
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

4.  Human pituitary corticotroph adenomas in vitro: morphologic and functional responses to corticotropin-releasing hormone and cortisol.

Authors:  S E Horvath; S L Asa; K Kovacs; L A Adams; W Singer; H S Smyth
Journal:  Neuroendocrinology       Date:  1990-03       Impact factor: 4.914

5.  ACTH and beta-endorphin secretion by three corticotrophic adenomas in culture. Effects of culture time, dexamethasone, vasopressin and synthetic corticotrophin releasing factor.

Authors:  R Oosterom; T Verleun; P Uitterlinden; W H Hackeng; J P Burbach; V M Wiegant; S W Lamberts
Journal:  Acta Endocrinol (Copenh)       Date:  1984-05

6.  Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study.

Authors:  K Kovacs; L Stefaneanu; S Ezzat; H S Smyth
Journal:  Arch Pathol Lab Med       Date:  1994-05       Impact factor: 5.534

7.  Effect of SMS 201-995, a long-acting somatostatin analogue, on the secretion and morphology of a pituitary growth hormone cell adenoma.

Authors:  S R George; K Kovacs; S L Asa; E Horvath; E G Cross; G N Burrow
Journal:  Clin Endocrinol (Oxf)       Date:  1987-04       Impact factor: 3.478

8.  Nelson's syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene.

Authors:  M Karl; G Von Wichert; E Kempter; D A Katz; M Reincke; H Mönig; I U Ali; C A Stratakis; E H Oldfield; G P Chrousos; H M Schulte
Journal:  J Clin Endocrinol Metab       Date:  1996-01       Impact factor: 5.958

9.  In vitro corticotropin-releasing hormone (CRH) stimulation of adrenocorticotropin release from corticotroph adenoma cells: effect of prolonged exposure to CRH and its interaction with cortisol.

Authors:  M Grino; F Boudouresque; B Conte-Devolx; G Gunz; F Grisoli; C Oliver; P Jaquet
Journal:  J Clin Endocrinol Metab       Date:  1988-04       Impact factor: 5.958

10.  [GRF and human somatotropic adenoma. In vivo and in vitro correlations between GH release and morphological and immunocytochemical aspects].

Authors:  B Loras; J Y Li; A Durand; J Trouillas; G Sassolas; C Girod
Journal:  Ann Endocrinol (Paris)       Date:  1985       Impact factor: 2.478
View more
  5 in total

Review 1.  Clinical Impact of the Current WHO Classification of Pituitary Adenomas.

Authors:  W Saeger; J Honegger; M Theodoropoulou; U J Knappe; C Schöfl; S Petersenn; R Buslei
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

2.  Total Barley Maiya Alkaloids Prevent Increased Prolactin Levels Caused by Antipsychotic Drugs and Reduce Dopamine Receptor D2 via Epigenetic Mechanisms.

Authors:  Yu-Ling Cao; Li -Zhu; Hong Zhang; Jun-Hua Meng; Hua-Jun Wu; Xiong Wang; Jin-Hu Wu; Ji-Li Zou; Mao-Sheng Fang; Jing An; Yong-Gang Chen
Journal:  Front Pharmacol       Date:  2022-07-05       Impact factor: 5.988

3.  Decreased expression of APAF-1 and increased expression of cathepsin B in invasive pituitary adenoma.

Authors:  Cristiana Tanase; Radu Albulescu; Elena Codrici; Bogdan Calenic; Ionela Daniela Popescu; Simona Mihai; Laura Necula; Maria Linda Cruceru; Mihail Eugen Hinescu
Journal:  Onco Targets Ther       Date:  2014-12-22       Impact factor: 4.147

4.  Short-term Preoperative Octreotide for Thyrotropin-secreting Pituitary Adenoma.

Authors:  Hong-Juan Fang; Yu Fu; Huan-Wen Wu; Yi-Lin Sun; Yang-Fang Li; Ya-Zhuo Zhang; Li-Yong Zhong
Journal:  Chin Med J (Engl)       Date:  2017-04-20       Impact factor: 2.628

5.  Fetal Alcohol Exposure Reduces Dopamine Receptor D2 and Increases Pituitary Weight and Prolactin Production via Epigenetic Mechanisms.

Authors:  Omkaram Gangisetty; Olivia Wynne; Shaima Jabbar; Cara Nasello; Dipak K Sarkar
Journal:  PLoS One       Date:  2015-10-28       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.